BARINTHUS BIOTHERAPEUTICS PL
BRNSNASDAQTrading Snapshot
- Day Range
- $0.74 – $0.74
- 52-Week Range
- $0.51 – $1.83
- Volume
- $2.36B
- Avg Volume
- $2.20B
- Shares Outstanding
- 40.8M
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $472,301
- P/E Ratio
- -0.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.02
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.0%
Why Investors Own BRNS
- ✓High-growth profile — revenue up +43.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 35% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BARINTHUS BIOTHERAPEUTICS PL
BRNS
StockOtter · stockotter.spaceAbout BARINTHUS BIOTHERAPEUTICS PL
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year?
Here is how Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) and Agilent Technologies (A) have performed compared to their sector so far this year.
Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics
Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; t